Cargando…
Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies
In diabetes, increased accumulation of sorbitol has been associated with diabetic complications through polyol pathway. Aldose reductase (AR) is one of the key factors involved in reduction of glucose to sorbitol, thereby its inhibition is important for the management of diabetic complications. In t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080350/ https://www.ncbi.nlm.nih.gov/pubmed/33906691 http://dx.doi.org/10.1186/s13065-021-00756-z |
_version_ | 1783685405840769024 |
---|---|
author | Bacha, Mohsinul Mulk Nadeem, Humaira Zaib, Sumera Sarwar, Sadia Imran, Aqeel Rahman, Shafiq Ur Ali, Hafiz Saqib Arif, Muazzam Iqbal, Jamshed |
author_facet | Bacha, Mohsinul Mulk Nadeem, Humaira Zaib, Sumera Sarwar, Sadia Imran, Aqeel Rahman, Shafiq Ur Ali, Hafiz Saqib Arif, Muazzam Iqbal, Jamshed |
author_sort | Bacha, Mohsinul Mulk |
collection | PubMed |
description | In diabetes, increased accumulation of sorbitol has been associated with diabetic complications through polyol pathway. Aldose reductase (AR) is one of the key factors involved in reduction of glucose to sorbitol, thereby its inhibition is important for the management of diabetic complications. In the present study, a series of seven 4-oxo-2-thioxo-1,3-thiazolidin-3-yl acetamide derivatives 3(a–g) were synthesized by the reaction of 5-(4-hydroxy-3-methoxybenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl acetic acid (2a) and 5-(4-methoxybenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl acetic acid (2b) with different amines. The synthesized compounds 3(a–g) were investigated for their in vitro aldehyde reductase (ALR1) and aldose reductase (ALR2) enzyme inhibitory potential. Compound 3c, 3d, 3e, and 3f showed ALR1 inhibition at lower micromolar concentration whereas all the compounds were more active than the standard inhibitor valproic acid. Most of the compounds were active against ALR2 but compound 3a and 3f showed higher inhibition than the standard drug sulindac. Overall, the most potent compound against aldose reductase was 3f with an inhibitory concentration of 0.12 ± 0.01 µM. In vitro results showed that vanillin derivatives exhibited better activity against both aldehyde reductase and aldose reductase. The molecular docking studies were carried out to investigate the binding affinities of synthesized derivatives with both ALR1 and ALR2. The binding site analysis of potent compounds revealed similar interactions as were found by cognate ligands within the active sites of enzymes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13065-021-00756-z. |
format | Online Article Text |
id | pubmed-8080350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-80803502021-04-29 Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies Bacha, Mohsinul Mulk Nadeem, Humaira Zaib, Sumera Sarwar, Sadia Imran, Aqeel Rahman, Shafiq Ur Ali, Hafiz Saqib Arif, Muazzam Iqbal, Jamshed BMC Chem Research Article In diabetes, increased accumulation of sorbitol has been associated with diabetic complications through polyol pathway. Aldose reductase (AR) is one of the key factors involved in reduction of glucose to sorbitol, thereby its inhibition is important for the management of diabetic complications. In the present study, a series of seven 4-oxo-2-thioxo-1,3-thiazolidin-3-yl acetamide derivatives 3(a–g) were synthesized by the reaction of 5-(4-hydroxy-3-methoxybenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl acetic acid (2a) and 5-(4-methoxybenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl acetic acid (2b) with different amines. The synthesized compounds 3(a–g) were investigated for their in vitro aldehyde reductase (ALR1) and aldose reductase (ALR2) enzyme inhibitory potential. Compound 3c, 3d, 3e, and 3f showed ALR1 inhibition at lower micromolar concentration whereas all the compounds were more active than the standard inhibitor valproic acid. Most of the compounds were active against ALR2 but compound 3a and 3f showed higher inhibition than the standard drug sulindac. Overall, the most potent compound against aldose reductase was 3f with an inhibitory concentration of 0.12 ± 0.01 µM. In vitro results showed that vanillin derivatives exhibited better activity against both aldehyde reductase and aldose reductase. The molecular docking studies were carried out to investigate the binding affinities of synthesized derivatives with both ALR1 and ALR2. The binding site analysis of potent compounds revealed similar interactions as were found by cognate ligands within the active sites of enzymes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13065-021-00756-z. Springer International Publishing 2021-04-27 /pmc/articles/PMC8080350/ /pubmed/33906691 http://dx.doi.org/10.1186/s13065-021-00756-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Bacha, Mohsinul Mulk Nadeem, Humaira Zaib, Sumera Sarwar, Sadia Imran, Aqeel Rahman, Shafiq Ur Ali, Hafiz Saqib Arif, Muazzam Iqbal, Jamshed Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies |
title | Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies |
title_full | Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies |
title_fullStr | Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies |
title_full_unstemmed | Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies |
title_short | Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies |
title_sort | rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080350/ https://www.ncbi.nlm.nih.gov/pubmed/33906691 http://dx.doi.org/10.1186/s13065-021-00756-z |
work_keys_str_mv | AT bachamohsinulmulk rhodanine3acetamidederivativesasaldoseandaldehydereductaseinhibitorstotreatdiabeticcomplicationssynthesisbiologicalevaluationmoleculardockingandsimulationstudies AT nadeemhumaira rhodanine3acetamidederivativesasaldoseandaldehydereductaseinhibitorstotreatdiabeticcomplicationssynthesisbiologicalevaluationmoleculardockingandsimulationstudies AT zaibsumera rhodanine3acetamidederivativesasaldoseandaldehydereductaseinhibitorstotreatdiabeticcomplicationssynthesisbiologicalevaluationmoleculardockingandsimulationstudies AT sarwarsadia rhodanine3acetamidederivativesasaldoseandaldehydereductaseinhibitorstotreatdiabeticcomplicationssynthesisbiologicalevaluationmoleculardockingandsimulationstudies AT imranaqeel rhodanine3acetamidederivativesasaldoseandaldehydereductaseinhibitorstotreatdiabeticcomplicationssynthesisbiologicalevaluationmoleculardockingandsimulationstudies AT rahmanshafiqur rhodanine3acetamidederivativesasaldoseandaldehydereductaseinhibitorstotreatdiabeticcomplicationssynthesisbiologicalevaluationmoleculardockingandsimulationstudies AT alihafizsaqib rhodanine3acetamidederivativesasaldoseandaldehydereductaseinhibitorstotreatdiabeticcomplicationssynthesisbiologicalevaluationmoleculardockingandsimulationstudies AT arifmuazzam rhodanine3acetamidederivativesasaldoseandaldehydereductaseinhibitorstotreatdiabeticcomplicationssynthesisbiologicalevaluationmoleculardockingandsimulationstudies AT iqbaljamshed rhodanine3acetamidederivativesasaldoseandaldehydereductaseinhibitorstotreatdiabeticcomplicationssynthesisbiologicalevaluationmoleculardockingandsimulationstudies |